AIDS-Related Kaposi's Sarcoma - Pipeline Review, Q3 2011

Global Markets Direct, July 2011, Pages: 63

AIDS-Related Kaposi's Sarcoma - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'AIDS-Related Kaposi's Sarcoma - Pipeline Review, Q3 2011', provides an overview of the AIDS-Related Kaposi's Sarcoma therapeutic pipeline. This report provides information on the therapeutic development for AIDS-Related Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS-Related Kaposi's Sarcoma. 'AIDS-Related Kaposi's Sarcoma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for AIDS-Related Kaposi's Sarcoma.
- A review of the AIDS-Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the AIDS-Related Kaposi's Sarcoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for AIDS-Related Kaposi's Sarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding AIDS-Related Kaposi's Sarcoma pipeline depth and focus of AIDS-Related Kaposi's Sarcoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
AIDS-Related Kaposi's Sarcoma Overview
Therapeutics Development
AIDS-Related Kaposi's Sarcoma Therapeutics under Development by Companies
AIDS-Related Kaposi's Sarcoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Pre-Clinical Stage Products
AIDS-Related Kaposi's Sarcoma Therapeutics - Products under Development by Companies
AIDS-Related Kaposi's Sarcoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in AIDS-Related Kaposi's Sarcoma Therapeutics Development
AIDS-Related Kaposi's Sarcoma - Therapeutics Assessment
Late Stage Drug Profiles
AIDS-Related Kaposi's Sarcoma Therapeutics – Drug Profile Updates
AIDS-Related Kaposi's Sarcoma Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for AIDS-Related Kaposi's Sarcoma, Q3 2011
Products under Development for AIDS-Related Kaposi's Sarcoma – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Aphios Corporation, 2011
PTC Therapeutics, Inc., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
AIDS-Related Kaposi's Sarcoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for AIDS-Related Kaposi's Sarcoma, Q3 2011
Products under Development for AIDS-Related Kaposi's Sarcoma – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Customers who bought this item also bought

• AIDS - Related Kaposi's Sarcoma – Pipeline Review, H1 2013
• Soft Tissue Sarcoma - Pipeline Review, Q4 2010
• Oncology Partnering Terms and Agreements
• HIV / AIDS – Pipeline Review, H1 2013
• HIV / AIDS - Pipeline Review, H2 2012
• HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth
• HIV/AIDS – The Jennings Report: Redefining the Size, Scope, and Scale of the AIDS Epidemic by Forensic Review of the Medical Literature
• Myelodysplastic Syndrome - Pipeline Review, Q3 2011
• Chemotherapy Effects - Pipeline Review, Q3 2011
• Hidradenitis Suppurativa - Pipeline Review, Q3 2011